Effect of MK0524A on Flushing Caused by Niacin (0524A-056)

Summary

The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.

Timeline

Start

2007-04

Primary completion

2007-08

Completion

2007-08

Publications

• Background Kush D, Hu DY, Ye P, Kim HS, Chen E, Sirah W, McCrary Sisk C, Paolini JF, Maccubbin D. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. 2009;114(3):192-8. doi: 10.1159/000228585. Epub 2009 Jul 15.

Drugs

Indications